Is the incidence of schizophrenia in South-East London really 10 times higher than in Santiago, Spain?

2782048744_3fc0d9280c_b

Vishal Bhavsar reviews an EU study of nearly 3,000 people across 6 EU countries, looking at the treated incidence of schizophrenia and psychotic disorders. It helps us better understand who gets psychosis, when, and where.

[read the full story...]

Behavioural and psychological symptoms of dementia: GPs’ perspective on management

woman-65675_1920

Marie Crabbe presents the findings of a mixed-methods systematic review, which looks at General Practitioners’ knowledge, attitudes and experiences of managing behavioural and psychological symptoms of dementia.

[read the full story...]

Is income inequality damaging our mental health?

alice-pasqual-258250-unsplash

Andy Bell from Centre for Mental Health writes his debut elf blog on a systematic review of income inequality and depression, which explores the associations between the two, but also the likely causes of these associations.

[read the full story...]

A roadmap to advance dementia research and care by 2025

treasure-map-1850653_1280

Clarissa Giebel unfolds and reviews a new roadmap to advance dementia research in prevention, diagnosis, intervention and care by 2025.

[read the full story...]

What can genetics tell us about the link between cannabis and schizophrenia? #MHQT

chase-fade-1055517-unsplash

Suzi Gage summarises a recent GWAS of lifetime cannabis use, which reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Interesting new evidence ahead of our Mental Health Question Time #MHQT event in London tomorrow.

[read the full story...]

Medical cannabis for mental illness: current use is not supported by research #MHQT

sharon-mccutcheon-798864-unsplash

As we prepare for our Cannabis #MHQT event on Wed 26 Sep, Luke Sheridan Rains dissects a narrative review that asks: Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?

His answer is that current evidence does not support the use of medical cannabis for mental illnesses such as anxiety or depression.

[read the full story...]

The cost of persuasive design: digital media use and ADHD

play-again

Elvira Perez Vallejos and David Daley consider the findings of a recent cohort study in JAMA that looks into the association between digital media use and subsequent symptoms of ADHD in adolescents.

[read the full story...]

Depression and anxiety: two sides of the same coin? #TransDX2018

96154801_b37e0edd8b_o

Ava Schulz reviews a paper by Mansell and McEvoy which looks at psychopathology in a heterogenous clinical sample of anxiety and depression.

[read the full story...]

Transdiagnostic and disorder-specific anxiety disorder treatments have equivalent treatment effects #TransDX2018

pawel-czerwinski-716699-unsplash

Jill Newby and Peter Norton blog an RCT on the unified protocol for transdiagnostic treatment of emotional disorders compared with diagnosis-specific protocols for anxiety disorders.

[read the full story...]

The transdiagnostic approach to anxiety: the case is made (again!) #TransDX2018

ben-white-170383-unsplash

Warren Mansell considers a review by Peter Norton and Daniel Paulus on the theoretical and empirical underpinnings of transdiagnostic models of anxiety disorder.

[read the full story...]